<?xml version="1.0" encoding="UTF-8"?>
<p>Overall, MTX and the other non-biologic agents should be considered as low risk treatment for HBVr in patients with both chronic and resolved HBV infection. Nevertheless, for those agents with potential direct hepatotoxic effect (MTX, LEF), appropriate monitoring precautions should always be in place.</p>
